Galaxy Biomedical Investment Co., Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was CNY 781.439 million compared to CNY 761.259 million a year ago. Operating loss was CNY 951.978 million compared to CNY 698.275 million a year ago. Net loss was CNY 1,146.867 million compared to CNY 705.963 million a year ago. Basic loss per share from continuing operations was CNY 1.0427 compared to CNY 0.6418 a year ago.